Glenmark Pharmaceuticals Ltd vs Lupin Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2173 as of 12 Jun 15:30 . The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 yearsThe P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 28.2 on March 2025 . This represents a CAGR of -5.84% over 5 years The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 yearsThe Market Cap of Lupin Ltd changed from ₹ 46318 crore on March 2021 to ₹ 92522 crore on March 2025 . This represents a CAGR of 14.84% over 5 years The revenue of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 3959 crore as compare to the Dec '25 revenue of ₹ 3945 crore. This represent the growth of 0.37% The revenue of Lupin Ltd for the Mar '26 is ₹ 7615 crore as compare to the Dec '25 revenue of ₹ 7282 crore. This represent the growth of 4.57% The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 578.28 crore as compare to the Dec '25 ebitda of ₹ 729.88 crore. This represent the decline of -20.77% The ebitda of Lupin Ltd for the Mar '26 is ₹ 2494 crore as compare to the Dec '25 ebitda of ₹ 1949 crore. This represent the growth of 27.95% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 301.32 crore over 8 quarters. This represents a CAGR of -5.89% The net profit of Lupin Ltd changed from ₹ 805.54 crore to ₹ 1468 crore over 8 quarters. This represents a CAGR of 35.03% The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 yearsThe Dividend Payout of Lupin Ltd changed from 23.43 % on March 2021 to 13.79 % on March 2025 . This represents a CAGR of -10.06% over 5 years .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

About Lupin Ltd

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Lupin Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Lupin Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 61,327 Cr while Market cap of Lupin Ltd is 104,829 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Lupin Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Lupin Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Lupin Ltd?

As of June 14, 2026, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2173.2. On the other hand, Lupin Ltd stock price is INR ₹2292.7.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Lupin Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Lupin Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.